Stable Liposomal Formulations for Ocular Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ocular drug delivery methods, such as eye drops and intravitreal injections, face challenges including poor bioavailability, stability issues with liposomal formulations, and the need for frequent injections, which can lead to complications and increased costs.
Innovation Solution
Development of stable liposomal formulations with modified preparation methods and additives to enhance stability and drug release properties, including the use of PEGylation for extended release, allowing for the encapsulation of both small and macromolecular drugs, and coating of intraocular lenses with biodegradable polymers for sustained antibiotic release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional liposomal formulations are used, then the structure provides basic drug encapsulation, but the stability is poor due to phospholipid oxidation and hydrolysis
Solution Approach 1:
The patent modifies the chemical parameters of the liposome components by replacing conventional phospholipids with oxidized phospholipids and adjusting cholesterol content to specific ratios (e.g., 3:1 or 4:1 molar ratios of oxidized phospholipid to cholesterol). This parameter change fundamentally alters the stability characteristics of the liposome formulation, preventing oxidation and hydrolysis while extending shelf life to over 40 days.
Solution Approach 2:
The patent creates a composite liposomal system by combining oxidized phospholipids with cholesterol in specific ratios, forming a stable phospholipid-cholesterol complex. This composite material approach leverages the complementary properties of both components: oxidized phospholipids provide structural stability while cholesterol enhances membrane rigidity and reduces permeability, together achieving superior stability and shelf life.
2Stability of the object's composition
If high concentration of cholesterol is used to stabilize phospholipid bilayers, then stability increases, but encapsulation efficiency decreases and drug release becomes very slow
Solution Approach 1:
The patent optimizes the cholesterol concentration parameter to specific ranges (3:1 or 4:1 molar ratios of oxidized phospholipid to cholesterol) rather than using high concentrations. This parameter optimization maintains bilayer stability while preventing excessive rigidity, thereby preserving encapsulation efficiency and enabling controlled drug release over extended periods without the drawbacks of high cholesterol formulations.
3Quantity of substance
If low concentration of cholesterol is used, then encapsulation efficiency increases, but drug release becomes very fast reducing stability
Solution Approach 1:
The patent modifies the cholesterol concentration parameter to optimal levels (3:1 or 4:1 ratios) that balance encapsulation efficiency with bilayer stability. This optimized parameter setting ensures sufficient cholesterol content to maintain structural integrity and control drug release rate, while avoiding the instability associated with low cholesterol formulations.
Solution Approach 2:
The patent introduces oxidized phospholipids as an intermediary component that mediates between cholesterol and the drug payload. This intermediary substance enhances bilayer stability and controls drug release kinetics without requiring high cholesterol concentrations, thereby maintaining both encapsulation efficiency and formulation stability simultaneously.
4Reliability
If frequent intravitreal injections are administered, then treatment effectiveness is maintained, but complications increase including endophthalmitis, increased IOP, retinal detachment, and development of glaucoma and cataracts
Solution Approach 1:
The patent incorporates antibiotics and anti-inflammatory agents into the liposomal formulation before administration. This preliminary action provides prophylactic protection against infections and inflammatory responses that would otherwise result from repeated intravitreal injections, thereby reducing complications while maintaining treatment effectiveness over extended periods.
Solution Approach 2:
The patent extends the duration of drug action from weeks to over 40 days through stable liposomal formulations with controlled release mechanisms. This continuity of useful action eliminates the need for frequent repeat injections, thereby reducing the cumulative risk of injection-related complications while maintaining continuous therapeutic effectiveness.
5Ease of operation
If eye drops are applied externally, then administration is simple, but bioavailability is poor due to lacrimation and impermeability through corneal epithelium
Solution Approach 1:
The patent modifies the physical and chemical parameters of the drug delivery system by using liposomal encapsulation with optimized size (50-200 nm), charge, and composition. These parameter changes enable the formulation to penetrate the corneal epithelium effectively while resisting lacrimal clearance, thereby achieving high ocular bioavailability through simple topical application without requiring invasive procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting formulations achieve a prolonged drug release of up to 180-200 days, reducing the frequency of injections and the risk of infections, while maintaining effective treatment for ocular diseases like AMD and endophthalmitis, thereby lowering treatment costs and improving patient compliance.
Implementation Method 1
Liposomes are a possible choice for sustained release ocular drug delivery because of their amphiphilic nature
Implementation Method 2
The first major problem is the stability and low shelf life. These can be attributed to the fact that the phospholipids which form these liposomes are highly prone to oxidation and hydrolysis
Implementation Method 3
But, in order to further prolong the time of release, the surface of liposomes was modified by using PEG. This increased time of release to approximately 180-200 days in vitro
Implementation Method 4
coating of intraocular lenses with biodegradable polymers for sustained antibiotic release
Implementation Method 5
In addition, lacrimation and impermeability through the corneal epithelium are responsible for poor ocular bioavailability
Implementation Method 6
the epithelial layer of the cornea allows hydrophobic drugs to pass, whereas the stroma (the next layer) allows hydrophilic drugs to pass, not hydrophobic
Data Source
AI summary
A system is disclosed for simple, non-invasive, sustained delivery of ophthalmic substances to the interior of the eye, for the prevention and treatment of eye diseases and conditions. Liposomes and inverted micelles are disclosed as suitable vehicles, and timed release of the substances is effected. Delivery methods include coating of a lens or injection into the eye.